Association between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs

Keyphrases

• 340B 100%
• Affordable Care Act 5%
• Balanced Panel 5%
• Bevacizumab 5%
• Cancer Treatment 5%
• Commercial Insurance 100%
• Commercially Insured 11%
• Control Variables 5%
• COVID-19 Pandemic 5%
• Difference Analysis 5%
• Difference-in-differences Model 5%
• Drug Expenditure 17%
• Drug Pricing 11%
• Drug Use 5%
• Female Patients 5%
• Filgrastim 5%
• Fixed Effects 11%
• Heterogeneous Groups 5%
• Hospitalized Patients 11%
• In Cancer 5%
• In Care 5%
• Insured Population 5%
• Medicare 5%
• Medicare Part B 5%
• Oncology Drugs 100%
• Pegfilgrastim 5%
• Program Participant 5%
• Program Participation 100%
• Reimbursement 5%
• Rituximab 5%
• Rural Setting 5%
• Time Effect 5%
• Total Drug 5%
• Trastuzumab 5%
• Unintended Consequences 5%

Medicine and Dentistry

• Bevacizumab 33%
• Biological Product 33%
• Cancer Therapy 33%
• Cohort Analysis 66%
• COVID-19 33%
• Filgrastim 33%
• Medicare 66%
• Oncology 100%
• Outpatient 100%
• Pegfilgrastim 33%
• Rituximab 33%
• Trastuzumab 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Bevacizumab 50%
• Biological Product 50%
• Cohort Study 100%
• Filgrastim 50%
• Malignant Neoplasm 50%
• Pandemic 50%
• Pegfilgrastim 50%
• Rituximab 50%
• Trastuzumab 50%